Susquehanna International Group, LLP Gritstone Bio, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$0.62 - $2.35 $89,838 - $340,515	-144,900 Reduced 29.72%	342,700 $212,000
Q1 2024 May 07, 2024	BUY	$1.96 - $2.9 $721,672 - $1.07 Million	368,200 Added 308.38%	487,600 $1.25 Million
Q4 2023 Feb 14, 2024	BUY	$1.28 - $2.85 $152,832 - $340,290	119,400 New	119,400 $243,000
Q2 2023 Aug 11, 2023	BUY	$1.66 - $3.03 $73,206 - $133,623	44,100 New	44,100 $85,000
Q3 2022 Nov 14, 2022	BUY	$2.46 - $4.75 $91,020 - $175,750	37,000 Added 195.77%	55,900 $144,000
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $97,350 - $238,700	-55,000 Reduced 74.42%	18,900 $46,000
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $208,754 - $631,442	-51,800 Reduced 41.21%	73,900 $304,000
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $326,748 - $511,383	-37,300 Reduced 22.88%	125,700 $1.62 Million
Q3 2021 Nov 15, 2021	BUY	$6.41 - $13.54 $888,426 - $1.88 Million	138,600 Added 568.03%	163,000 $1.76 Million
Q2 2021 Aug 11, 2021	BUY	$8.13 - $10.2 $110,568 - $138,720	13,600 Added 125.93%	24,400 $223,000
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $43,956 - $292,788	10,800 New	10,800 $102,000

37.5M

1.46M

168K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $16.1M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.